Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.70 |
| ▸ | CCR5 | P51681 | 11/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241015 | 0.87 | CCR5 (0.65) | CCR5OPRM1OPRL1 | |
| SCHEMBL5864068 | 0.85 | AGER (0.57) | CHRM2CHRM3CCR5OPRM1 | |
| SCHEMBL5863894 | 0.85 | CHRM2 (0.51) | CHRM2CHRM3CCR5OPRM1 | |
| SCHEMBL5863862 | 0.83 | AGER (0.49) | CHRM2CHRM3CCR5OPRM1 | |
| SCHEMBL7244920 | 0.82 | CCR5 (0.85) | CCR5 | |
| SCHEMBL5863954 | 0.79 | AGER (0.54) | CHRM2CHRM3CCR5OPRM1 | |
| SCHEMBL5863674 | 0.79 | AGER (0.49) | CHRM2CHRM3CCR5 | |
| SCHEMBL4025012 | 0.78 | CCR5 (0.81) | CCR5 | |
| SCHEMBL8293386 | 0.78 | CTSD (0.78) | CHRM2CHRM3OPRM1 | |
| SCHEMBL5863781 | 0.77 | AGER (0.55) | CHRM2CHRM3CCR5OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166590-A1 | Microsomal triglyceride transfer protein | WETTERAU JOHN R (US) | 2003-09-04 | — | — | US | claimed |
| US-20030166590-A1 | Microsomal triglyceride transfer protein | WETTERAU JOHN R (US) | 2003-09-04 | — | — | US | disclosed |
| US-6492365-B1 | Microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-5789197-A | GENETIC ENGINEERING | E. R. SQUIBB & SONS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5595872-A | DNA SEQUENCES, CELLS AND EXPRESSION VECTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166590-A1 | Microsomal triglyceride transfer protein | MTTP, CETP, HDLBP | CHRM2 4754/4885CHRM3 4798/4885CCR5 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.